Clinical trial NCT02350777: T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
Official title: Phase II Trial of T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Hematopoietic Stem Cell Transplant
Poor Marrow Graft Function
Keywords: T-cell Depleted Hematopoietic Stem Cell
Allogeneic Hematopoietic Stem Cell Transplantation
CliniMACS Cell Selection System
14-228
HSCT
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2015-01-30
Enrollment: 4
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if giving the patient stem cells their original donor (boost) after removing the T cells (T cell depleted- TCD boost) without further chemotherapy. The investigators want to see if this can improve bone marrow function. This would also improve the patients white blood counts, red blood counts and platelets. This may make the patients chances of improving and surviving better. The investigators will also be looking at the short term side effects and risks of the TCD boost.


Eligibility criteria: Inclusion Criteria:

* Patients who are diagnosed with PGF are candidates for this trial.
* Patients who underwent transplant at another facility and suffer from PGF will be eligible as well as long as a donor is available. PGF can be primary (no counts recovery after the preparative regimen) or secondary (cytopenia after engraftment has occurred).
* Patients with auto-immune cytopenia with auto antibodies to neutrophils or platelets or positive Coombs test that did not respond to immunosuppressive agents within 3 months from initiation of therapy are eligible as well.
* Persistent cytopenia requiring growth factors and/or blood products AND evidence of hypocellular BM (\<25%). Persistent cytopenia (at least 4 weeks period) is defined by presence of TWO of the following:

  1. ANC \<1.0x10\^9/L without filgrastim support or any ANC value that requires recurrent support by filgrastim (administered at least once a week).
  2. Plt\<50x10\^9/L
  3. Hb\<8 or PRBC transfusion dependent (once every 2 weeks or more) with reticulocyte count of \< 40x10\^9/L.

This criteria for persistent cytopenia and hypocellular bone marrow does not apply to patients with auto-immune cytopenia, ONLY PGF patients

* Full donor myeloid chimerism. Patients after T cell depletion transplant can have a significant mixed T cell chimerism and this can affect the testing of marrow chimerism. In this case, the neutrophil chimerism will be used to determine eligibility for this trial. Patients will be excluded if neutrophils are less than 90% donor cells; a higher percentage of host cells could be due to relapse or impending relapse.
* Age: pediatrics and adults patients. No age exclusion.
* Each patient must be willing to participate as a research subject and must sign an informed consent form.
* For infections and end organs related criteria (at time of TCD boost administration) see table in protocol.

Exclusion Criteria:

Patients will be excluded from the trial if at time of enrollment:

* Evidence of relapsed disease by morphologic, cytogenetic or molecular diagnostic tools.
* Hypersplenism documented by imaging study (US or CT)
* Pregnant women
* Patient who underwent TCD boost without counts recovery and are considered for another TCD boost will be treated off protocol.

Primary outcomes:
measure: Peripheral Blood Counts Recovery (Response Will be Defined by Stable Blood Counts (ANC>1000, Hb>8 With Absolute Reticulocyte Count>20x10^9/L ,and Plt>50,000) Without Support of Blood Product Transfusions and/or Growth Factors.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Roni Tamari, MD
role: PRINCIPAL_INVESTIGATOR
References: